BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Executive Summary
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.